Cargando…
1363. Does Genotypic Testing Improve Treatment Outcomes in Drug-Resistant Tuberculosis?
BACKGROUND: Treatment of drug-resistant tuberculosis (DR-TB) requires toxic and complex drug regimens. Dismal outcomes occur due to a delay in the report of susceptibility results. WHO endorses genotypic tests like line probe assay (Mtbdrsl) for an early diagnosis enabling start of robust treatment...
Autores principales: | Thampy, Anupa, Ninan, Marilyn, Sarojini Michael, Joy, Rupali, Priscilla |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6809207/ http://dx.doi.org/10.1093/ofid/ofz360.1227 |
Ejemplares similares
-
1363. Assessment and Quantification of Nasopharyngeal Streptococcus pneumoniae Colonization Does Not Discriminate Between Children with Viral and Bacterial Respiratory Infection
por: Pernica, Jeffrey, et al.
Publicado: (2020) -
1363. Sulopenem Activity Against Enterobacteriaceae Isolates From Patients With Urinary Tract Infection or Intra-Abdominal Infection
por: Puttagunta, Sailaja, et al.
Publicado: (2018) -
Extensively drug-resistant tuberculosis in India: A review
por: Michael, Joy Sarojini, et al.
Publicado: (2012) -
Further Elucidation of Galactose Utilization in Lactococcus lactis MG1363
por: Solopova, Ana, et al.
Publicado: (2018) -
Cryptococcosis with Tuberculosis: Overlooked Coinfections
por: Suresh, Christina S, et al.
Publicado: (2021)